Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

Simple item page
dc.contributor.authorImai, C.
dc.contributor.authorMihara, K.
dc.contributor.authorAndreansky, M.
dc.contributor.authorNicholson, I.
dc.contributor.authorPui, C.
dc.contributor.authorGeiger, T.
dc.contributor.authorCampana, D.
dc.date.issued2004
dc.description.abstractTo develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8alpha, and the signaling domain of CD3zeta. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-zeta') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-zeta receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-zeta lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB-zeta-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.
dc.description.statementofresponsibilityC Imai, K Mihara, M Andreansky, I C Nicholson, C-H Pui, T L Geiger and D Campana
dc.identifier.citationLeukemia, 2004; 18(4):676-684
dc.identifier.doi10.1038/sj.leu.2403302
dc.identifier.issn0887-6924
dc.identifier.issn1476-5551
dc.identifier.urihttp://hdl.handle.net/2440/54942
dc.language.isoen
dc.publisherNature Publishing Group
dc.source.urihttps://doi.org/10.1038/sj.leu.2403302
dc.subjectT-cell receptor
dc.subjectCD137
dc.subjectacute lymphoblastic leukemia
dc.subjectB-cell lymphoma
dc.titleChimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Paediatrics publications